JP2020523373A - ガルシノールの抗肥満の潜在能力 - Google Patents

ガルシノールの抗肥満の潜在能力 Download PDF

Info

Publication number
JP2020523373A
JP2020523373A JP2019569248A JP2019569248A JP2020523373A JP 2020523373 A JP2020523373 A JP 2020523373A JP 2019569248 A JP2019569248 A JP 2019569248A JP 2019569248 A JP2019569248 A JP 2019569248A JP 2020523373 A JP2020523373 A JP 2020523373A
Authority
JP
Japan
Prior art keywords
garcinol
mammal
fat
bacteroides
obesity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019569248A
Other languages
English (en)
Japanese (ja)
Inventor
ムハンメド マジード
ムハンメド マジード
カリヤナム ナガブシャナム
カリヤナム ナガブシャナム
ラクシュミ ムンドクル
ラクシュミ ムンドクル
Original Assignee
サミ ラブズ リミテッド
サミ ラブズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サミ ラブズ リミテッド, サミ ラブズ リミテッド filed Critical サミ ラブズ リミテッド
Publication of JP2020523373A publication Critical patent/JP2020523373A/ja
Priority to JP2021130804A priority Critical patent/JP2021185156A/ja
Priority to JP2022067326A priority patent/JP2022097521A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Confectionery (AREA)
JP2019569248A 2017-06-15 2018-06-13 ガルシノールの抗肥満の潜在能力 Pending JP2020523373A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021130804A JP2021185156A (ja) 2017-06-15 2021-08-10 ガルシノールの抗肥満の潜在能力
JP2022067326A JP2022097521A (ja) 2017-06-15 2022-04-15 ガルシノールの抗肥満の潜在能力

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762519949P 2017-06-15 2017-06-15
US62/519,949 2017-06-15
US201762523611P 2017-06-22 2017-06-22
US62/523,611 2017-06-22
PCT/US2018/037242 WO2018231923A1 (en) 2017-06-15 2018-06-13 Anti-obesity potential of garcinol

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2021130804A Division JP2021185156A (ja) 2017-06-15 2021-08-10 ガルシノールの抗肥満の潜在能力
JP2022067326A Division JP2022097521A (ja) 2017-06-15 2022-04-15 ガルシノールの抗肥満の潜在能力

Publications (1)

Publication Number Publication Date
JP2020523373A true JP2020523373A (ja) 2020-08-06

Family

ID=64659462

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019569248A Pending JP2020523373A (ja) 2017-06-15 2018-06-13 ガルシノールの抗肥満の潜在能力
JP2021130804A Pending JP2021185156A (ja) 2017-06-15 2021-08-10 ガルシノールの抗肥満の潜在能力
JP2022067326A Pending JP2022097521A (ja) 2017-06-15 2022-04-15 ガルシノールの抗肥満の潜在能力

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021130804A Pending JP2021185156A (ja) 2017-06-15 2021-08-10 ガルシノールの抗肥満の潜在能力
JP2022067326A Pending JP2022097521A (ja) 2017-06-15 2022-04-15 ガルシノールの抗肥満の潜在能力

Country Status (8)

Country Link
EP (1) EP3638226A4 (ko)
JP (3) JP2020523373A (ko)
KR (1) KR102289324B1 (ko)
AU (1) AU2018284354A1 (ko)
BR (1) BR112019026824A2 (ko)
CA (1) CA3066446A1 (ko)
MX (1) MX2019014841A (ko)
WO (1) WO2018231923A1 (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102136335B1 (ko) * 2020-03-24 2020-07-22 (주)메디톡스 간기능 개선 또는 지방축적 억제 미생물 및 그의 용도
KR102363092B1 (ko) * 2020-06-19 2022-02-16 한국식품연구원 장내 미생물을 이용한 비만 위험도 예측 또는 진단용 조성물, 그를 이용한 진단키트, 정보제공방법 및 비만 예방 또는 치료제 스크리닝 방법
KR102191487B1 (ko) * 2020-06-19 2020-12-15 (주)메디톡스 간기능 개선 또는 지방축적 억제 미생물 및 그의 용도
KR102363088B1 (ko) * 2020-06-19 2022-02-16 한국식품연구원 장내 미생물을 이용한 당뇨병 위험도 예측 또는 진단용 조성물, 그를 이용한 진단키트, 정보제공방법 및 당뇨병 예방 또는 치료제 스크리닝 방법
KR102363098B1 (ko) * 2020-06-19 2022-02-16 한국식품연구원 장내 미생물을 이용한 신질환 위험도 예측 또는 진단용 조성물, 그를 이용한 진단키트, 정보제공방법 및 신질환 예방 또는 치료제 스크리닝 방법
KR102363094B1 (ko) * 2020-06-19 2022-02-16 한국식품연구원 장내 미생물을 이용한 간질환 위험도 예측 또는 진단용 조성물, 그를 이용한 진단키트, 정보제공방법 및 간질환 예방 또는 치료제 스크리닝 방법
KR102331485B1 (ko) 2021-08-02 2021-12-01 주식회사 바이오뱅크힐링 블라우티아 웩슬러래 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
CN114605242A (zh) * 2022-04-11 2022-06-10 澳门大学 间苯三酚类化合物的制备方法与药物、保健产品和食品
CN114847475B (zh) * 2022-07-05 2022-11-29 广东金骏康生物技术有限公司 一种促进akk菌生长的发酵槐米粉的应用
CN115637242A (zh) * 2022-10-20 2023-01-24 中南大学 微生物复合菌剂及其制备方法和赤泥原位生物脱碱的方法
CN116903760A (zh) * 2023-05-25 2023-10-20 浙江大学 木耳多糖及其制备方法和抑制肥胖的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000044468A (ja) * 1998-07-29 2000-02-15 Kikkoman Corp リパーゼ阻害剤及び抗肥満剤又は高脂血症抑制剤
JP2004506657A (ja) * 2000-08-17 2004-03-04 サビンサ　コーポレーション 天然および合成ｈｃａのバイオアベイラブルな組成物
US20120178801A1 (en) * 2011-01-10 2012-07-12 Muhammed Majeed Compositions and its use in treating obesity or inducing weight loss

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011352073B2 (en) * 2010-12-30 2015-12-24 Sami Labs Limited Hepatoprotectant activity of garcinol
CA3092318A1 (en) * 2012-09-20 2014-03-27 Prothera, Inc. Probiotic compositions and methods for the treatment of obesity and obesity-related conditions
US9872840B2 (en) * 2013-10-03 2018-01-23 Delhi Institute Of Pharmaceutical Sciences And Research Effect of garcinol in delaying the progression of diabetic nephropathy
KR102356094B1 (ko) * 2014-03-24 2022-01-26 주식회사 다이셀 약학 조성물
CA2934156A1 (en) * 2015-11-10 2017-05-10 Muhammed Majeed Use of forskolin in the treatment of obesity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000044468A (ja) * 1998-07-29 2000-02-15 Kikkoman Corp リパーゼ阻害剤及び抗肥満剤又は高脂血症抑制剤
JP2004506657A (ja) * 2000-08-17 2004-03-04 サビンサ　コーポレーション 天然および合成ｈｃａのバイオアベイラブルな組成物
US20120178801A1 (en) * 2011-01-10 2012-07-12 Muhammed Majeed Compositions and its use in treating obesity or inducing weight loss

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BIOSCI.BIOTECHNOL.BIOCHEM., vol. 72, JPN6021008114, 2008, pages 1772 - 1780, ISSN: 0004663783 *
FOOD AND FUNCTION, vol. 3, JPN6021008118, 2012, pages 49 - 57, ISSN: 0004459447 *
INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, vol. 1, JPN6021008117, 2010, pages 175 - 181, ISSN: 0004459446 *
NUTRAFOODS, vol. 8, JPN6021008116, 2009, pages 17 - 26, ISSN: 0004459445 *
SCIENTIFIC REPORTS, vol. 6, JPN6021008115, 2016, pages 33566, ISSN: 0004459444 *

Also Published As

Publication number Publication date
JP2021185156A (ja) 2021-12-09
KR20200012978A (ko) 2020-02-05
WO2018231923A1 (en) 2018-12-20
BR112019026824A2 (pt) 2020-06-30
EP3638226A4 (en) 2021-04-07
KR102289324B1 (ko) 2021-08-12
EP3638226A1 (en) 2020-04-22
MX2019014841A (es) 2020-02-17
JP2022097521A (ja) 2022-06-30
AU2018284354A1 (en) 2020-01-16
CA3066446A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
JP2020523373A (ja) ガルシノールの抗肥満の潜在能力
He et al. Rhizoma Coptidis alkaloids alleviate hyperlipidemia in B6 mice by modulating gut microbiota and bile acid pathways
JP6954563B2 (ja) 代謝障害を処置するための低温殺菌アッカーマンシアの使用
Zhao et al. Pomegranate peel polyphenols reduce chronic low-grade inflammatory responses by modulating gut microbiota and decreasing colonic tissue damage in rats fed a high-fat diet
Liu et al. Grape seed proanthocyanidin extract ameliorates inflammation and adiposity by modulating gut microbiota in high‐fat diet mice
Tang et al. A synbiotic consisting of Lactobacillus plantarum S58 and hull-less barley β-glucan ameliorates lipid accumulation in mice fed with a high-fat diet by activating AMPK signaling and modulating the gut microbiota
Zhang et al. 25‐Hydroxyvitamin D3‐enhanced PTPN 2 positively regulates periodontal inflammation through the JAK/STAT pathway in human oral keratinocytes and a mouse model of type 2 diabetes mellitus
JP2018532779A (ja) 糖尿病及び腸疾患の治療又は予防における使用のためのフィーカリバクテリウムプラウスニッツィ及びデスルホビブリオピゲル
Ge et al. Luteolin cooperated with metformin hydrochloride alleviates lipid metabolism disorders and optimizes intestinal flora compositions of high-fat diet mice
Yan et al. Oryzanol alleviates high fat and cholesterol diet-induced hypercholesterolemia associated with the modulation of the gut microbiota in hamsters
Dai et al. Anti-inflammatory effects of newly synthesized α-galacto-oligosaccharides on dextran sulfate sodium-induced colitis in C57BL/6J mice
KR20160069492A (ko) 박테로이데스 에시디페시언스를 유효성분으로 포함하는, 대사성 질환 예방 또는 치료용 약학적 조성물
US20200030388A1 (en) Compositions for modifying gut microbiota
Ding et al. N-Acetylcysteine alleviates high fat diet-induced hepatic steatosis and liver injury via regulating the intestinal microecology in mice
US20180360776A1 (en) Anti-obesity potential of garcinol
Sheykhsaran et al. Gut microbiota and obesity: an overview of microbiota to microbial-based therapies
Yan et al. Gut dysbiosis correction contributes to the hepatoprotective effects of Thymus quinquecostatus Celak extract against alcohol through the gut–liver axis
Xiao et al. Neohesperidin dihydrochalcone ameliorates high-fat diet-induced glycolipid metabolism disorder in rats
Zhang et al. M2 macrophages infusion ameliorates obesity and insulin resistance by remodeling inflammatory/macrophages' homeostasis in obese mice
JP2021527669A (ja) 線維症の軽減又は治療のための組成物及び方法
Zhang et al. Fermented soybean powder containing Bacillus subtilis SJLH001 protects against obesity in mice by improving transport function and inhibiting angiogenesis
He et al. Mangiferin alleviates trimethylamine-N-oxide (TMAO)-induced atherogenesis and modulates gut microbiota in mice
Zhang et al. MUP1 mediates urolithin A alleviation of chronic alcohol-related liver disease via gut-microbiota-liver axis
Wen et al. Alleviating Effect of Mulberry Leaf 1-Deoxynojirimycin on Resistin-Induced Hepatic Steatosis and Insulin Resistance in Mice
Li et al. Astragaloside IV alleviates macrophage senescence and d-galactose-induced bone loss in mice through STING/NF-κB pathway

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200407

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200407

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210810

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211215